lymphocyte antigen 6 family member DGenealiases: E48 · Ly-6D
Q-omics provides the consensus-scored LY6D profile across patient tissues and cancer cell-line models. LY6D expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, LY6D is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, LY6D protein abundance shows 12,115 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight PAAD, LUAD, and HNSC as cancer lineages where LY6D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6D survival associations across molecular data types. LY6D RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6D RNA expression–survival associations across cancer types. High LY6D expression shows unfavorable associations in PAAD, UVM, SKCM, KIRC and MESO, but favorable associations in ACC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for LY6D RNA expression.
This table summarizes LY6D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LY6D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6D shows lower tumor expression in BRCA and higher tumor expression in LUAD, LUSC, THCA, UCEC and BLCA. The LUAD box plot shows higher LY6D RNA expression in tumor versus normal tissue (log2 FC = +3.226, t-test p < 0.001).
This table shows molecular features associated with LY6D in patient tissues and cancer cell lines. In patient samples, LY6D shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, LY6D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_NSCLC_LUAD.
